MEDICLINK provides advanced human fat(adipose) tissue derived mesenchymal stem cell(ADMSC) pro-cessing services at MEDICLINK's PIC/S GMP facility and standardized ADMSC products to the highest standard of purity(>99%), viability and safety.


MEDICLINK has a team of experts dedicated to stem cell research since 2001. With over 50 stem cell research publications in top peer-reviewed scientific journals to date, including a number of world-first breakthrough and discoveries, and Patents, MEDICLINK leads the way by scientific excellence.

MEDICLINK's autologous and allogeneic adopose-derived MSC products, produced under PIC/S GMP guideline, have been approved by the Taiwan Food and Drug Administration(TFDA) for use in human clinical trials.